Cardiovascular
ICON's cardiovascular trial experience, supported by a global team of experts
Obesity and beyond
Embracing multi-indication potential during clinical development
The obesity therapeutic marketplace has rapidly embraced multi-indication drug development, following successful label expansion of incretin agonists semaglutide and tirzepatide. Explore the rise of multi-indication drug development across cardiometabolic-related conditions and the strategies driving clinical and commercial success for molecules with broad potential.
.jpeg?crop=yes&w=310&h=310&itok=0TSwfTVm "obesity_scan_icons"){kind=icon}
Survey report
How today’s obesity developers are navigating a multi-indication landscape
From January 24 to March 5, 2025, ICON conducted a survey of 155 developers in obesity and related comorbidities. Survey respondents shared their clinical development and commercialisation strategies for molecules with broad clinical and commercial potential, and factors influencing whether or not to pursue multi-indication development of agents in their pipeline.
.jpeg?crop=yes&w=310&h=310&itok=C8L7ju0i "obesity scan person"){kind=icon}
A multifaceted risk factor: Addressing obesity's impact across the disease spectrum
With obesity as a risk factor across the disease spectrum, there are several unique considerations and strategies for sponsors and researchers to account for in their approach to development and clinical trials for obesity treatment.
Mitigating the impact of COVID-19 on cardiovascular trials
COVID-19 has had a significant impact on the conduct of clinical trials and participants. Participants in cardiovascular (CV) trials typically are older, with underlying CV disease or risk factors such as hypertension and diabetes – a population at higher risk of death from COVID-19 if they contract the virus. As a result, these individuals may have heightened concerns about participating in a clinical trial due to the potential for exposure to COVID-19. Discover measures that can be implemented in ongoing trials to ensure the safety of participants, maximise retention and maintain trial integrity.
From genomics to the coming of age glycomics
Discover how glycan biomarkers are quickly becoming key elements of cancer, cardiovascular, and gastrointestinal research, setting the stage for a new golden age of epigenetic research and personalised therapeutics.
.jpg?crop=yes&w=310&h=310&itok=qcYu7ZZ_ "Glycomics-Whitepaper_powerpoint3-(1)"){kind=icon}
Reimagining patient-centric clinical trials with the IoMT
Follow a theoretical patient through the entire clinical trial journey – from initial contact for an early study through transition to treatment with an approved product. At each stage, we explore how IoMT can increase clinical development programme efficiency by reducing the burden on patients, caregivers, pharma companies and medical device and diagnostic manufacturers.
Cardiovascular event adjudication during COVID-19 and beyond
In this webinar you will learn more about best practices for cardiovascular event adjudication across drug and device trials, including recent advances in the selection and application of connected devices.
Latest on Cardiovascular, Metabolic, and Circulation
If you would like to receive our Cardiovascular email updates, including the latest on cardiovascular clinical trials, click here to go to our preference centre.
Blogs and media articles relating to cardiovascular and metabolic clinical trials
-
Media article: Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimising clinical trial outcomes and guiding effective treatments.
-
Media article: The Next Wave of Biosimilars: Why Hematology Is a High-Stakes Opportunity
A confluence of patent expiries and rising healthcare costs are accelerating both interest and investment in biosimilars across the world. Nowhere is this more apparent than in hematology.
-
Media article: Beyond the Drug: How Human Factors Shape CVOT Success
ICON experts, Dr Emad Basta and Dr. Jack L Martin discuss how cardiovascular outcomes trials (CVOTs) are essential to ensuring drug safety, regulatory compliance, and clinical impact in this new article. Please find ICON's piece on page 24-25.
-
Media article: Clinical trials - Keeping pace with shifting drug development paradigms for multi-indication therapies
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
Blog: Modern tools for cardiovascular studies
Cardiovascular disease is the leading global cause of death, driving urgent research efforts. CV studies are key to evaluating heart-related treatments and impacts. Digital health technologies (DHTs) now play a growing role, improving data capture and patient-centricity in CV research.
-
Media article: Unlocking the potential of GLP-1 based therapies with RWE
A recent ICON survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
Media article: Cardiovascular outcomes trials revisited – methodological enhancements for greater clinical relevance.
ICON experts, Pierre Martineau and Adrienne Stoudenmire, share key considerations for successful CVOTs including study design, data strategy and technology in this new article.
-
Media article: Embracing proactive multi-indication development for metabolic therapies
In this article, ICON expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
Cardiovascular clinical trials services at ICON
ICON has over 25 years' experience conducting cardiovascular trials, with particular emphasis on key cardiovascular/metabolic indications: heart failure, lipid disorders, diabetes, renal insufficiency and renal transplant, arrhythmia, and rare diseases.